Corcept Therapeutics (CORT) Total Liabilities (2010 - 2026)

Corcept Therapeutics has reported Total Liabilities for 17 years, with the latest figure at $182.9 million in Q2 2026.

• Quarterly Total Liabilities rose 10.24% year-over-year to $182.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $182.9 million (up 10.24% YoY) and the FY2025 annual result came in at $188.8 million, up 17.32% from the prior year.
• Total Liabilities climbed to $182.9 million in Q2 2026 per CORT's latest filing, from $176.9 million in the prior quarter.
• Over five years, Total Liabilities peaked at $191.7 million in Q3 2025 and troughed at $54.0 million in Q2 2022.
• A 5-year average of $127.6 million and a median of $125.3 million in 2023 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2023 and 2026: Total Liabilities surged 120.97% in 2023, then advanced 8.41% in 2026.
• Over 5 years, Total Liabilities stood at $81.6 million in 2022, then surged by 40.72% to $114.8 million in 2023, then surged by 40.2% to $161.0 million in 2024, then increased by 17.32% to $188.8 million in 2025, then dropped by 3.13% to $182.9 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $182.9 million, $176.9 million, and $188.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.